FDA places Atara’s Biothearapeutics’ cancer, autoimmune therapies on hold
The US drug regulator has put a clinical hold on Atara Biotherapeutics’ T-cell therapies for cancer and autoimmune diseases after issues were observed.
Drugs
Health
Pharma
Daiichi Sankyo sets up robotic lab in US to speed up drug discovery
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.
Drugs
Pharma
Research
New insights on GLP-1 drugs: Benefits and risks unveiled
HQ Team January 21, 2024: The popular diabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists such as Ozempic, have gained immense popularity for their.
Drugs
Health
Pharma
AstraZeneca’s medicine to treat a type of breast cancer gets US nod
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs
Health
Pharma
US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.
Drugs
Health
Medical
Eli Lilly’s Omvoh gains FDA approval for treating Crohn’s disease
HQ Team The US Food and Drug Administration (FDA) has approved Eli Lilly’s Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active.
Drugs
Medical
Research
India’s Tata Group grants $57.8 million to build medical school in IT capital
Tata Group, a $165 billion Indian conglomerate, is set to build a medical school in the southern technology hub of Bengaluru by partnering.
Drugs
Health
Pharma
Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.
Drugs
Health
Medical
Eli Lilly to buy Scorpion Therapeutics’ cancer drug for $2.5 billion
Eli Lilly and Company will acquire Scorpion Therapeutics’ investigational cancer drug, currently being evaluated in first- mid-stage trials to treat breast and solid.
Drugs
Medical
Pharma
Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.